Dashboard
1
Poor Management Efficiency with a low ROCE of 2.44%
- The company has been able to generate a Return on Capital Employed (avg) of 2.44% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
3
Flat results in Sep 25
4
With ROE of 4.65%, it has a attractive valuation with a 2.38 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
SAR 3,434 Million (Small Cap)
51.00
NA
0.00%
0.69
7.79%
2.22
Revenue and Profits:
Net Sales:
415 Million
(Quarterly Results - Sep 2025)
Net Profit:
44 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.87%
0%
-1.87%
6 Months
-5.96%
0%
-5.96%
1 Year
-1.7%
0%
-1.7%
2 Years
-27.45%
0%
-27.45%
3 Years
-18.09%
0%
-18.09%
4 Years
-39.16%
0%
-39.16%
5 Years
2.76%
0%
2.76%
Saudi Pharmaceutical Industries & Medical Appliances Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-1.36%
EBIT Growth (5y)
66.36%
EBIT to Interest (avg)
0.76
Debt to EBITDA (avg)
170.08
Net Debt to Equity (avg)
0.83
Sales to Capital Employed (avg)
0.58
Tax Ratio
40.66%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.44%
ROE (avg)
2.09%
Valuation key factors
Factor
Value
P/E Ratio
51
Industry P/E
Price to Book Value
2.38
EV to EBIT
35.68
EV to EBITDA
20.76
EV to Capital Employed
1.79
EV to Sales
2.75
PEG Ratio
0.15
Dividend Yield
NA
ROCE (Latest)
5.01%
ROE (Latest)
4.65%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
415.30
447.30
-7.15%
Operating Profit (PBDIT) excl Other Income
82.60
38.50
114.55%
Interest
23.20
22.80
1.75%
Exceptional Items
-2.00
4.30
-146.51%
Consolidate Net Profit
43.60
-9.30
568.82%
Operating Profit Margin (Excl OI)
124.00%
35.70%
8.83%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is -7.15% vs 17.22% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is 568.82% vs 75.78% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,682.00
1,655.40
1.61%
Operating Profit (PBDIT) excl Other Income
203.90
102.20
99.51%
Interest
95.80
74.30
28.94%
Exceptional Items
5.00
-20.50
124.39%
Consolidate Net Profit
31.80
-40.00
179.50%
Operating Profit Margin (Excl OI)
70.90%
12.20%
5.87%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 1.61% vs 16.43% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 179.50% vs 74.76% in Dec 2023
About Saudi Pharmaceutical Industries & Medical Appliances Corp. 
Saudi Pharmaceutical Industries & Medical Appliances Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






